Outset Medical, Inc. (NASDAQ:OM – Get Free Report) General Counsel John Brottem sold 2,632 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $4.39, for a total transaction of $11,554.48. Following the completion of the transaction, the general counsel owned 87,475 shares of the company’s stock, valued at approximately $384,015.25. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Outset Medical Stock Performance
NASDAQ:OM opened at $4.30 on Friday. Outset Medical, Inc. has a one year low of $3.00 and a one year high of $16.16. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11. The company’s 50-day simple moving average is $4.57 and its 200 day simple moving average is $4.22. The firm has a market capitalization of $80.83 million, a P/E ratio of -1.05 and a beta of 1.96.
Outset Medical (NASDAQ:OM – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%.The business had revenue of $31.64 million during the quarter, compared to analysts’ expectations of $28.97 million. As a group, analysts forecast that Outset Medical, Inc. will post -3.8 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Report on Outset Medical
Institutional Trading of Outset Medical
Institutional investors and hedge funds have recently bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new position in Outset Medical in the fourth quarter worth about $29,000. Legal & General Group Plc bought a new position in shares of Outset Medical in the second quarter worth approximately $34,000. BNP Paribas Financial Markets grew its holdings in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Outset Medical during the fourth quarter valued at approximately $46,000. Finally, HRT Financial LP bought a new stake in shares of Outset Medical during the fourth quarter valued at approximately $58,000.
About Outset Medical
Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.
Featured Articles
- Five stocks we like better than Outset Medical
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.
